[Oncolytic viruses for therapy of malignant glioma].

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Biomeditsinskaia khimiia

• Publication date

  2016-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.18097/PBMC20166204376PMID 27562991
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oncolytics Biotech® Inc.: REOLYSIN® for melanoma therapy.

  2015cited by this paper
• Molecular Pathways Molecular Pathways : Multimodal Cancer-Killing Mechanisms Employed by Oncolytic Vesiculoviruses

  2013cited by this paper
• Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model

  2013cited by this paper
• Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.

  2013cited by this paper
• Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol

  2012cited by this paper
• Oncolytic measles virus strains have significant antitumor activity against glioma stem cells

  2012cited by this paper
• Preferential Replication of Systemically Delivered Oncolytic Vaccinia Virus in Focally Irradiated Glioma Xenografts

  2012cited by this paper
• Heparan sulfate sulfatase SULF2 regulates PDGFRα signaling and growth in human and mouse malignant glioma.

  2012cited by this paper
• Oncolytic Virus Therapy for Glioblastoma Multiforme: Concepts and Candidates

  2012cited by this paper
• A Novel Oncolytic Herpes Simplex Virus that Synergizes with Phosphoinositide 3-kinase/Akt Pathway Inhibitors to Target Glioblastoma Stem Cells

  2011cited by this paper
• Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma.

  2011cited by this paper
• Enhanced Antitumor Efficacy of Low-Dose Etoposide with Oncolytic Herpes Simplex Virus in Human Glioblastoma Stem Cell Xenografts

  2011cited by this paper
• Thunder and lightning: immunotherapy and oncolytic viruses collide.

  2011cited by this paper
• Oncolytic vaccinia virus for the treatment of cancer

  2011cited by this paper
• Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil.

  2010cited by this paper
• Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models.

  2010cited by this paper
• Efficacy and Safety/Toxicity Study of Recombinant Vaccinia Virus JX-594 in Two Immunocompetent Animal Models of Glioma

  2010cited by this paper
• Translation Control by Protein Kinase R Restricts Minute Virus of Mice Infection: Role in Parvovirus Oncolysis

  2010cited by this paper
• Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin.

  2010cited by this paper
• Oncolytic parvoviruses as cancer therapeutics.

  2010cited by this paper
• Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.

  2009cited by this paper
• Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo

  2009cited by this paper
• Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas.

  2009cited by this paper
• Efficacy of Systemically Administered Oncolytic Vaccinia Virotherapy for Malignant Gliomas Is Enhanced by Combination Therapy with Rapamycin or Cyclophosphamide

  2009cited by this paper
• Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.

  2009cited by this paper
• Oncolytic viral therapy of malignant glioma

  2009cited by this paper
• Newcastle diseases virus strain V4UPM displayed oncolytic ability against experimental human malignant glioma

  2009cited by this paper
• Systemic Vesicular Stomatitis Virus Selectively Destroys Multifocal Glioma and Metastatic Carcinoma in Brain

  2008cited by this paper
• Toxicology Study of Repeat Intracerebral Administration of a Measles Virus Derivative Producing Carcinoembryonic Antigen in Rhesus Macaques in Support of a Phase I/II Clinical Trial for Patients with Recurrent Gliomas

  2008cited by this paper
• Malignant gliomas in adults.

  2008cited by this paper
• Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity.

  2008cited by this paper
• Gene therapy progress and prospects cancer: oncolytic viruses

  2008cited by this paper
• Interleukin-13 Displaying Retargeted Oncolytic Measles Virus Strains Have Significant Activity Against Gliomas With Improved Specificity.

  2008cited by this paper
• Growth phenotypes and biosafety profiles in poliovirus‐receptor transgenic mice of recombinant oncolytic polio/human rhinoviruses

  2008cited by this paper
• Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial

  2008cited by this paper
• Comparative evaluation of survivin, midkine, and CXCR4 promoters for transcriptional targeting of glioma gene therapy

  2007cited by this paper
• Survivin-Driven and Fiber-Modified Oncolytic Adenovirus Exhibits Potent Antitumor Activity in Established Intracranial Glioma

  2007cited by this paper
• Cytosolic Activation of Cathepsins Mediates Parvovirus H-1-Induced Killing of Cisplatin and TRAIL-Resistant Glioma Cells

  2007cited by this paper
• History of oncolytic viruses: genesis to genetic engineering.

  2007cited by this paper
• Molecularly targeted therapy for malignant glioma

  2007cited by this paper
• RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations

  2007cited by this paper
• Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice.

  2007cited by this paper
• Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

  2007cited by this paper
• Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1.

  2006cited by this paper
• Activated MEK Suppresses Activation of PKR and Enables Efficient Replication and In Vivo Oncolysis by Δγ134.5 Mutants of Herpes Simplex Virus 1

  2006cited by this paper
• Variable Deficiencies in the Interferon Response Enhance Susceptibility to Vesicular Stomatitis Virus Oncolytic Actions in Glioblastoma Cells but Not in Normal Human Glial Cells

  2006cited by this paper
• CD46 Represents a Target for Adenoviral Gene Therapy of Malignant Glioma

  2006cited by this paper
• Conditionally replicative adenoviral vectors for malignant glioma

  2006cited by this paper
• Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.

  2006cited by this paper
• Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme.

  2006cited by this paper
• Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity.

  2006cited by this paper
• Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas.

  2005cited by this paper
• Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.

  2005cited by this paper
• Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model.

  2005cited by this paper
• An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.

  2005cited by this paper
• Δ24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization

  2005cited by this paper
• Rescue and propagation of fully retargeted oncolytic measles viruses

  2005cited by this paper
• Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor.

  2004cited by this paper
• HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival

  2004cited by this paper
• MTH-68/H Oncolytic Viral Treatment in Human High-Grade Gliomas

  2004cited by this paper
• Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection.

  2004cited by this paper
• High CD46 Receptor Density Determines Preferential Killing of Tumor Cells by Oncolytic Measles Virus

  2004cited by this paper
• Poliovirus receptor CD155-targeted oncolysis of glioma.

  2004cited by this paper
• Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts

  2003cited by this paper
• Oncolytic Viruses: Clinical Applications as Vectors for the Treatment of Malignant Gliomas

  2003cited by this paper
• Oncolytic virus therapy using genetically engineered herpes simplex viruses

  2002cited by this paper
• Oncolytic virus therapy using genetically engineered herpes simplex viruses.

  2002cited by this paper
• Expression of the Human Poliovirus Receptor/CD155 Gene Is Activated by Sonic Hedgehog*

  2002cited by this paper
• Relative Neurotropism of a Recombinant Rhabdovirus Expressing a Green Fluorescent Envelope Glycoprotein

  2002cited by this paper
• Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene

  2002cited by this paper
• Reovirus as an oncolytic agent against experimental human malignant gliomas.

  2001cited by this paper
• Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.

  2001cited by this paper
• Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing

  2001cited by this paper
• Intergeneric poliovirus recombinants for the treatment of malignant glioma.

  2000cited by this paper
• A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo

  2000cited by this paper
• Attenuated, Replication-Competent Herpes Simplex Virus Type 1 Mutant G207: Safety Evaluation in Mice

  2000cited by this paper
• Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

  2000cited by this paper
• Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.

  2000cited by this paper
• Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

  2000cited by this paper
• Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.

  1999cited by this paper
• Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991.

  1998cited by this paper
• Measles Virus Spread and Pathogenesis in Genetically Modified Mice

  1998cited by this paper
• Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins

  1998cited by this paper
• Intracerebral injection of adenovirus harboring the HSVtk gene combined with ganciclovir administration: toxicity study in nonhuman primates

  1998cited by this paper
• Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants.

  1996cited by this paper
• Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

  1995cited by this paper
• Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus

  1993cited by this paper
• Newcastle disease virus selectively kills human tumor cells.

  1992cited by this paper
• Experimental therapy of human glioma by means of a genetically engineered virus mutant

  1991cited by this paper
• Measles virus: both the haemagglutinin and fusion glycoproteins are required for fusion.

  1991cited by this paper
• Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis.

  1990cited by this paper
• Susceptibility of human cells to killing by the parvoviruses H-1 and minute virus of mice correlates with viral transcription

  1990cited by this paper
• Uveal melanoma management.

  1989cited by this paper
• Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate.

  1989cited by this paper

• Anti-Cancer Virotherapy in Russia: Lessons from the Past, Current Challenges and Prospects for the Future.

  2022cites this paper
• Oncolytic Viruses in Tumor Therapy: The Russian Perspective

  2021cites this paper
• ОНКОЛИТИЧЕСКАЯ ВИРОТЕРАПИЯ В ЛЕЧЕНИИ ГЛИОБЛАСТОМЫ: ДОСТИЖЕНИЯ И ПРОБЛЕМЫ КЛИНИЧЕСКИХ ИССЛЕДОВАНИЙ (ОБЗОР ЛИТЕРАТУРЫ)

  2020cites this paper
• Oncolytic Activity of the Vaccine Strain of Type 3 Poliovirus on the Model of Rat Glioma C6 Cells

  2019cites this paper
• Glioblastoma Multiforme stem cells are highly sensitive to some human non-pathogenic enteroviruses

  2018cites this paper
• Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches.

  2017cites this paper